Related Experiment Video

Updated: Jul 14, 2026

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration
06:21

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration

Published on: April 27, 2018

Eradication of therapy-resistant human prostate tumors using a cancer terminator virus

Devanand Sarkar1, Irina V Lebedeva, Zao-zhong Su

  • 1Department of Urology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, College of Physicians and Surgeons, New York, New York 10032, USA.

Cancer Research
|June 5, 2007
PubMed

Insights

A novel cancer terminator virus (CTV) engineered to express MDA-7/IL-24 selectively targets and eliminates advanced prostate cancer cells, including resistant and metastatic tumors, offering a potential cure.

Area of Science:

  • Oncolytic virology
  • Molecular oncology
  • Cancer gene therapy

Background:

  • Terminal prostate cancer often overexpresses antiapoptotic proteins (Bcl-2, Bcl-xL), conferring resistance to conventional treatments.
  • Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24) exhibits cancer-selective apoptosis-inducing properties but its efficacy is limited by Bcl-2/Bcl-xL overexpression.

Purpose of the Study:

  • To develop a novel oncolytic adenovirus expressing mda-7/IL-24 under a cancer-specific promoter for enhanced prostate cancer therapy.
  • To overcome resistance mechanisms in prostate cancer by creating a virus that replicates selectively in cancer cells.

Main Methods:

  • Constructed a conditionally replication-competent adenovirus (Ad.PEG-E1A-mda-7) with E1A expression driven by the PEG-3 promoter and mda-7/IL-24 in the E3 region.
  • Evaluated cancer cell-selective replication, mda-7/IL-24 expression, growth inhibition, and apoptosis induction in normal and prostate cancer cells (including Bcl-2/Bcl-xL overexpressing).
  • Tested the therapeutic efficacy of Ad.PEG-E1A-mda-7 in xenograft models of advanced prostate cancer in athymic nude mice.

Main Results:

  • Ad.PEG-E1A-mda-7 demonstrated cancer cell-specific replication and mda-7/IL-24 expression, leading to significant growth inhibition and apoptosis in prostate cancer cells.
  • Treatment with Ad.PEG-E1A-mda-7 completely eradicated primary and distant tumors in xenograft models, suggesting a potential cure for metastatic disease.
  • The engineered virus effectively overcame Bcl-2 and Bcl-xL mediated resistance in prostate cancer cells.

Conclusions:

  • The developed cancer terminator virus (CTV), Ad.PEG-E1A-mda-7, shows potent and cancer-selective therapeutic activity against advanced and metastatic prostate cancer.
  • This novel oncolytic virus strategy holds promise for treating patients with refractory prostate cancer, including those with distant metastases.
  • Further investigation into this CTV approach could lead to new therapeutic options for advanced prostate cancer patients.

More Related Videos

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...